O'Berry Neuro-Medical Center

Neuros Medical Announces Completion of QUEST Pivotal Trial 90-day Primary Endpoints

Retrieved on: 
Monday, June 6, 2022
Gabapentinoid, CA, Company, IDE, Doctor of Philosophy, Neuros Technology, BSI, International Organization for Standardization, Pain, QUEST, O'Berry Neuro-Medical Center, Sale, Patient, ISO, Phantom limb, Technology, Chronic pain, Autumn, IPG, Peripheral nervous system, Certification, Safety, Medical device, Poultry, ALTIUS

ALISO VIEJO, Calif., June 6, 2022 /PRNewswire/ -- Neuros Medical, Inc., a medical device company developing an innovative, on-demand bioelectric nerve block therapy for patients with intractable post-amputation pain, announced today the completion of its QUEST Pivotal Trial 90-day primary endpoints.

Key Points: 
  • ALISO VIEJO, Calif., June 6, 2022 /PRNewswire/ -- Neuros Medical, Inc., a medical device company developing an innovative, on-demand bioelectric nerve block therapy for patients with intractable post-amputation pain, announced today the completion of its QUEST Pivotal Trial 90-day primary endpoints.
  • QUEST is a 180-subject randomized, double blinded, active sham controlled clinical trial that is being conducted under an Investigational Device Exemption (IDE).
  • QUEST is designed to assess the safety & effectiveness of the Company's AltiusBioelectric Nerve Block Technology to treat intractable post-amputation pain.
  • Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.

Neuros Medical Announces Completion of Enrollment in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain

Retrieved on: 
Wednesday, September 15, 2021
Case Western Reserve University, Gabapentinoid, IDE, DRS, O'Berry Neuro-Medical Center, Patient, Phantom, Company, Phantom limb, QUEST, Safety, Peripheral nervous system, Joe Byrd (Cherokee Nation Principal Chief), Neuros Technology, Chronic pain, Pain, IPG, Poultry, Medical device

QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.

Key Points: 
  • QUEST is designed to assess the safety & effectiveness of the Company's AltiusHigh-Frequency Nerve Block system to treat intractable post-amputation pain.
  • Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.
  • Neuros Medical, a neuromodulation company, has developed the Altius system for the treatment of chronic post-amputation pain (phantom limb pain and residual limb pain).
  • Post-amputation pain includes both phantom limb and residual limb (or "stump") pain, and impacts nearly one million Americans.

Unity HA Adds Jon J. Snyder as CEO, Announces Name Change to Realeve™

Retrieved on: 
Wednesday, August 18, 2021
General Health, Medical Devices, Alternative Medicine, Health, Pharmaceutical, Pain, Technology, Cyberon, ATI, Headache, Cardinal Health, Migraine, Cluster headache, Marketing, Tears, Pulsant, Patient, Interface (computing), CEO, SPG, US Foods, Eye, Trigeminal neuralgia, Snyder, FDA, Stroke, Suffering, View, O'Berry Neuro-Medical Center, Nasal congestion, Pharmaceutical industry, the Pulsante SPG Microstimulator System, Cluster Headache, Realeve, LLC, THE PULSANTE SPG MICROSTIMULATOR SYSTEM, CLUSTER HEADACHE, REALEVE, LLC

Unity HA today announced the addition of Jon J. Snyder as Chief Executive Officer.

Key Points: 
  • Unity HA today announced the addition of Jon J. Snyder as Chief Executive Officer.
  • The company also announced the change of their name from Unity HA, to Realeve, to support the commercialization process for their Pulsante SPG Microstimulator System for cluster headache.
  • Unity HA Founder, Dr. Peter Bonutti said, "We are extremely pleased to add a proven, medical device executive with strong neuromodulation and chronic pain therapy development experience in Jon Snyder to lead Realeve going forward."
  • Snyder added, "It is an honor to join the Realeve team and move this impactful therapy closer to the market.